Technical Articles

the long journey of cancer treatment, the emergence of immunotherapy was once regarded as a revolution. However, although immune checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) antibodies have achieved remarkable results in the treatment of various cancers, a large number of patients still develop resistance to them. This has led scientists to continuously explore new strategies to enhance the effects of immunotherapy. Recently, a study on CXCL10 has brought us new hope.